Literature DB >> 1969102

Intrathecal octreotide for cancer pain.

R D Penn, J A Paice, J S Kroin.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1969102     DOI: 10.1016/0140-6736(90)90861-x

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  8 in total

Review 1.  The epidural and intrathecal administration of somatotrophin-release inhibiting factor: native and synthetic analogues.

Authors:  D P Beltrutti; S Moessinger; G Varrassi
Journal:  Curr Rev Pain       Date:  2000

Review 2.  Patient-controlled spinal opiate analgesia in terminal cancer. Has its time really arrived?

Authors:  J Chrubasik; S Chrubasik; E Martin
Journal:  Drugs       Date:  1992-06       Impact factor: 9.546

Review 3.  Neurotransmitters in subcortical somatosensory pathways.

Authors:  J Broman
Journal:  Anat Embryol (Berl)       Date:  1994-03

4.  Indium-111 octreotide scintigraphy in patients with bone tumours of the extremities.

Authors:  S Inanir; M Unlü; B Okudan; E Cila; S Atik
Journal:  Eur J Nucl Med       Date:  1996-08

5.  Octreotide increases thresholds of colonic visceral perception in IBS patients without modifying muscle tone.

Authors:  M Bradette; M Delvaux; G Staumont; J Fioramonti; L Bueno; J Frexinos
Journal:  Dig Dis Sci       Date:  1994-06       Impact factor: 3.199

Review 6.  Octreotide in gastrointestinal motility disorders.

Authors:  C Owyang
Journal:  Gut       Date:  1994       Impact factor: 23.059

Review 7.  New drugs in the management of the irritable bowel syndrome.

Authors:  M J Farthing
Journal:  Drugs       Date:  1998-07       Impact factor: 9.546

Review 8.  Established and potential therapeutic applications of octreotide in palliative care.

Authors:  Eric E Prommer
Journal:  Support Care Cancer       Date:  2008-02-07       Impact factor: 3.603

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.